{"id":587997,"date":"2022-02-23T17:32:02","date_gmt":"2022-02-23T17:32:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=587997"},"modified":"2022-02-23T17:32:02","modified_gmt":"2022-02-23T17:32:02","slug":"chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-emerging-and-marketed-therapies-clinical-trials-and-treatment-algorithm-key-companies-teijin-octapharma-shire-takeda-argenx","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-emerging-and-marketed-therapies-clinical-trials-and-treatment-algorithm-key-companies-teijin-octapharma-shire-takeda-argenx_587997.html","title":{"rendered":"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline: Emerging and Marketed Therapies, Clinical Trials, and Treatment Algorithm | Key Companies &#8211; Teijin, Octapharma, Shire, Takeda, Argenx"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline: Emerging and Marketed Therapies, Clinical Trials, and Treatment Algorithm | Key Companies - Teijin, Octapharma, Shire, Takeda, Argenx\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline: Emerging and Marketed Therapies, Clinical Trials, and Treatment Algorithm | Key Companies - Teijin, Octapharma, Shire, Takeda, Argenx\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">\u201cChronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Insight, 2022&#8243; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Chronic Inflammatory Demyelinating Polyneuropathy Pipeline<\/strong> report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report also covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/d6d8dbd0ff0c9246e5ea4c0fc6936353.jpg\" alt=\"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Analysis\" \/><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights about companies that are developing therapies for the <strong>treatment of Chronic Inflammatory Demyelinating Polyneuropathy <\/strong>with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Chronic Inflammatory Demyelinating Polyneuropathy Treatment.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Chronic Inflammatory Demyelinating Polyneuropathy key companies<\/strong> involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Chronic Inflammatory Demyelinating Polyneuropathy Drugs<\/strong> under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Chronic Inflammatory Demyelinating Polyneuropathy market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample Pages @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Therapeutics Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key companies in the CIDP Market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Teijin Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Octapharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Shire<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Takeda<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Argenx<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">UCB Biopharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">MedDay Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">GeNeuro Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Momenta Pharmaceuticals<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chronic Inflammatory Demyelinating Polyneuropathy Therapies Covered in the Report Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">GGS-CIDP<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">NewGam<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">HyQvia<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Efgartigimod<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Rozanolixizumab<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">MD-1003<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">GNbAC1<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">M254<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many more.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request for Sample Pages @&nbsp; &nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Chronic Inflammatory Demyelinating Polyneuropathy&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Chronic Inflammatory Demyelinating Polyneuropathy Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Chronic Inflammatory Demyelinating Polyneuropathy &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Chronic Inflammatory Demyelinating Polyneuropathy Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Chronic Inflammatory Demyelinating Polyneuropathy Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Chronic Inflammatory Demyelinating Polyneuropathy Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Chronic Inflammatory Demyelinating Polyneuropathy Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Chronic Inflammatory Demyelinating Polyneuropathy Key Companies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Chronic Inflammatory Demyelinating Polyneuropathy Key Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Chronic Inflammatory Demyelinating Polyneuropathy Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Chronic Inflammatory Demyelinating Polyneuropathy Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Chronic Inflammatory Demyelinating Polyneuropathy Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Visit to get the sample report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Other Latest Healthcare Report by DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dysautonomia-autonomic-dysfunction-market\">Dysautonomia (Autonomic Dysfunction) Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Dysautonomia (Autonomic Dysfunction) Market<\/strong> is set to evolve in the coming years owing to the rising awareness of the disease, the launch of emerging therapies, and incremental healthcare spending across the world. Globally, some of the key companies such as <strong><em>Celltex Therapeutics, Theravance Biopharma, PTC Therapeutics,<\/em><\/strong> and several others are diligently working in the Dysautonomia (Autonomic Dysfunction) Market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-emerging-and-marketed-therapies-clinical-trials-and-treatment-algorithm-key-companies-teijin-octapharma-shire-takeda-argenx\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-emerging-and-marketed-therapies-clinical-trials-and-treatment-algorithm-key-companies-teijin-octapharma-shire-takeda-argenx\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP \u201cChronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Insight, 2022&#8243; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market. The Chronic Inflammatory Demyelinating Polyneuropathy Pipeline &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-emerging-and-marketed-therapies-clinical-trials-and-treatment-algorithm-key-companies-teijin-octapharma-shire-takeda-argenx_587997.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-587997","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/587997","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=587997"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/587997\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=587997"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=587997"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=587997"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}